Abstract: The subject matter of this invention is a composition and method of making a water-dispersible, stabilizing colloidal microcrystalline cellulose:xarboxymethylcellulose composition. The method of making the composition does not require a salt solution as an anti-slip agent.

Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.

Abstract: Antimicrobial formulations and coatings for medical devices and processes therefor are disclosed. The formulations include at least one water permeable polymer with at least one antimicrobial agent in a liquid medium and are prepared by wet milling the components and can form antimicrobial coatings having uniformly dispersed particles having an average size of no greater than 50 microns.

Abstract: Provided are prophylactic and therapeutic methods of treatment of subjects for the purpose of inhibiting vaso-occlusive events, including embolism, by administering agents, including anagrelide and anagrelide derivatives, which reduce the number of circulating platelets to low normal or to below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.

Abstract: There is disclosed a method for treating disorders modulated by at least opiate receptor activity or monoamine activity, including acute and chronic pain, comprising administering a pharmaceutical formulation comprising O-desmethyltramadol. Methods are also provided that are effective for overcoming resistance to tramadol in patients.

Abstract: The invention relates to the molecule having formula (I), as well as the enantiomers thereof, and to the use of same in the treatment of ADHD, narcolepsy or idiopathic hypersomnia.

Abstract: Compositions which include a corticosteroid in combination with an additional compound active in treatment of an inflammatory disorder are provided.

Abstract: Compositions are provided comprising a balance between lysine and essential amino acids and metabolizable energy. The compositions are useful in methods to prevent or treat obesity in an animal without concomitant loss of lean muscle mass. The compositions may also be used in methods to preserve or to cause a gain in lean muscle mass in an animal in need thereof.

Abstract: Methods and articles of manufacture for treating patients with degenerative bone are provided. The methods are useful to improve bone quality in a localized area of a degenerative bone (e.g., osteopenic or osteoporotic bone), such as by improving BMD to be substantially similar to BMD in an average, healthy individual at the age of peak BMD. The methods can comprise forming a void in a localized area of the degenerative bone and filling the void with a bone regenerative material that causes generation of new, healthy, natural bone material. The articles of manufacture can comprise kits formed of various materials useful in the inventive methods for improving bone quality.

Abstract: Homeopathic compositions. Implementations of topical homeopathic compositions may include an actives portion including a plurality of active ingredients and a base including a plurality of inactive ingredients where the plurality of active ingredients include tinctures and/or homeopathic preparations of Actaea spicata, Aesculus hippocastanum, Arnica montana, Atropa belladonna, Bellis perennis, Bryonia alba, Calendula officinalis, Causticum, Cimicifuga racemosa, Hypericum perforatum, Kali Carbonicum, Ledum palustre, Lithium Carbonicum, Rhododendron chrysanthum, Rhus toxicodendron, Ruta graveolens, Salicylicum Acidum, and Stellaria media and one or more tinctures and/or homeopathic preparations selected from the group consisting of Althaea officinalis, Caulophyllum thalictroides, Guaiacum, Rhamnus californica, or any combination thereof.

Abstract: The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen Ramalina terebrata, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (iNOS) in the transcription stage to significantly inhibit the production of nitric oxide (NO) that is a key mediator of inflammatory responses. In addition, it inhibits the activation of the inflammatory mediator NF-?B, inhibits p38 MAPK, ERK1/2 and JNK signaling pathways, and inhibits the expression of the LPS receptor TLR4, suggesting that Ramalin has an excellent anti-inflammatory effect. Thus, the composition containing Ramalin can be effectively used to fundamentally treat or prevent inflammatory diseases or immune diseases and to relieve or alleviate the symptoms of the diseases.

Abstract: A synthetic osteoinductive porous biomaterial is provided comprising: a network of interconnected micropores, wherein the microporosity is 23% by volume or more; wherein the surface free energy of the biomaterial is 19 mJ/m or more; and the mean interconnection diameter and the mean interconnection diameter and the surface free energy are chosen to provide a permeability resulting from the micropores of 0.206 nm2 or greater and a capillary pressure difference in water of 3.7 kPa or more. The biomaterial contains hydroxyapatite and silicon.

Abstract: A water-in-oil type sunscreening cosmetic material containing phenylbenzimidazole sulfonic acid, 2-amino-2-methyl-1,3-propanediol and/or 2-amino-2-(hydroxymethyl)propane-1,3-diol, and octyl methoxycinnamate.

Abstract: The bone graft system comprises a solid inorganic component, which is bone graft material, and a hydrogel. The hydrogel contains >2 ppm of silicon ions, calculated as parts by weight of Si per million of the aqueous component of the hydrogel. Preferably, the solid inorganic component comprises hydroxyapatite or a silicon-containing hydroxyapatite, and may be a silicon-containing hydroxyapatite having a Ca/P ratio in the range 2.05 to 2.55 and a Ca/(P+Si) molar ratio less than 1.66. Bone healing is promoted by delivery of silicon ion release from the hydrogel and by the solid inorganic component stimulating cell behavior.

Abstract: A capsule slurry including at least one coacervated capsule and at least 10 wt % humectant is disclosed. The humectant may be sorbitol, glycerin, polyethylene glycol, propylene glycol, xylitol, erythritol and/or betaine.

Abstract: A powdered mixture that may be added to the water or food of animals. The powder comprises a mixture, which includes brewer's yeast, Aronia extract, cranberry extract, and an omega-3 fatty acid (such as docosahexaenoic acid (DHA)). In some embodiments, the mixture of the powder also includes one or more of the following: an added amount of citric acid, potassium chloride, tricalcium phosphate, water-soluble egg membrane complex, an added amount of vitamin E, a meat flavor agent (such as natural bacon flavor), and other suitable ingredients.

Abstract: In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.

Abstract: A cosmetic water-based ink containing at least one acryl-based polymer, at least one polymeric ionic thickener, at least one anionic or amphoteric-ionic surfactant, at least one material in particle form and at least one non-ionic surfactant, wherein the non-ionic surfactant is a compound which contains between 4 and 8 units of PEG or PPG and a C6-C20 fatty acid residue.

Abstract: A colored fragrancing composition is provided that comprises, in a cosmetically acceptable medium: a) at least 2% by weight of a fragrancing substance relative to the total weight of the composition; b) at least one derivative of benzylidene camphor containing a sulphonic function or a benzotriazole silicone of particular formula (1) that will be defined below in detail; c) at least one dye that is soluble in said medium; said composition not containing an alkyl ?,??-diphenylacrylate compound or an alkyl ?-cyano-?,??-diphenylacrylate compound. Also provided is a cosmetic method for fragrancing human keratin substances and in particular the skin, lips and integuments, comprising the application to the keratin substances of the composition defined previously.

Abstract: A hygienic body wipe for an adult male. The body wipe comprises a non-woven fabric and a liquid composition that includes a body cleansing agent, a skin conditioning agent, a foaming agent, and water, and a pH of at least about 10.